Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Hims & Hers vs TeleClinic

Two GLP-1 desks, one scoreboard. We put Hims & Hers and TeleClinic head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 26 · Grade B

Hims & Hers

Visit Hims & Hers Full brief →

FDA warning letter, September 2025 — issued to Hims & Hers Health, Inc. dba Hims. See the FDA's warning letter database.

vs
No. 83 · Grade C

TeleClinic

Visit TeleClinic Full brief →

The verdict

Hims & Hers takes this head-to-head.

Hims & Hers scores 85 to 75 on our six-factor Brief Score — Mass-market, app-first weight program with nationwide reach — watch the compounded-supply headlines.

That doesn't make TeleClinic a bad call — it's best for readers who want transparent, cash-pay compounded glp-1 from a named 503a pharmacy across 47 states. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
83
36
Supply Reliability
86
87
Transparency
83
94
Access Breadth
88
84
Clinical Oversight
86
80
Track Record
86
79
Hims & HersBrief Score 85 · 75TeleClinic

Price, coverage & the tracker

Hims & HersTeleClinic
Brief Score85/100 (B)75/100 (C)
Semaglutide$199/moFrom $199/mo (compounded)
TirzepatideNot disclosedFrom $299/mo (compounded)
CoverageAll 50 states47 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
On the trackerRisingprice risingNewnew to the tracker, no prior reading

Hims & Hers: App-first reach is nationwide, but compounded supply has drawn industry-wide scrutiny.

TeleClinic: New to the tracker on 1 August 2026. The published line reads From $199/mo (compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole ranking at 94/100.

The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.